Evommune reports positive data from mid-stage development of eczema drug. The company focuses on the treatment of chronic inflammatory diseases, including atopic dermatitis (eczema). EVO756-AD001, a randomized, double-blind, placebo-controlled, multicenter phase 2b study in adults with moderate to severe atopic dermatitis, is ongoing. Participants receive EVO756 or placebo daily for 12 weeks and are assessed for safety and efficacy at scheduled visits. A 2-week final check-up follows the end of the treatment. The EVO301-AD001 study is Phase 2a and involves two intravenous administrations of EVO301 or placebo with evaluation over 12 weeks. Evommune is developing candidates targeting mast cells, sensory neurons and T-cells in inflammatory diseases.[1][2][4][7]